Preterm birth is a leading cause of infant deaths and illness in the U.S.—yet its underlying molecular causes remain largely unclear. About 40 to 50% of preterm births, defined as births before 37 weeks of pregnancy, are ...
Mar 9, 2021
0
32
Scientists from the Florida campus of The Scripps Research Institute (TSRI) have found new targets for potential intervention in breast cancer. These new targets could eventually increase effectiveness and reduce the undesirable ...
Jun 5, 2014
0
0
Research published in the July issue of The Journal of Nuclear Medicine shows imaging progesterone receptor (PR) status also may be able to identify responders and nonresponders to endocrine therapy at an early stage. Estrogen ...
Jul 2, 2012
0
0
Tamoxifen is a time-honored breast cancer drug used to treat millions of women with early-stage and less-aggressive disease, and now a University of Rochester Medical Center team has shown how to exploit tamoxifen's secondary ...
Apr 23, 2013
0
0
Researchers at The Pennsylvania State University College of Medicine, led by Dr. Ian S. Zagon, have discovered that a novel biological pathway, the OGF-OGFr axis, can be modulated in human triple-negative breast cancer cells ...
Aug 9, 2013
0
0
A new editorial paper titled "ERβ as a mediator of estrogen signaling in inflammatory breast cancer" has been published in Oncotarget.
Jul 3, 2023
0
1
(Medical Xpress)—Breast cancer can be curable if it's caught soon enough—unless it is the "triple negative" type more likely to target young, black or Hispanic women.
Jun 6, 2013
0
0
TNBC is a particularly aggressive subtype of breast cancer, characterized by the absence of three key receptors: estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Approximately ...
Jul 25, 2023
0
1
In a new paper in Cancer Cell, a team led by Judy Lieberman, PhD, of Boston Children's Hospital's Program in Cellular and Molecular Medicine reports "triple-negative" breast cancers may be vulnerable to drugs that attack ...
Aug 12, 2013
0
0
Physicians may soon have a new way to measure the efficacy or failure of hormone therapy for breast cancer patients, according to new research published in the February issue of The Journal of Nuclear Medicine. Researchers ...
Feb 11, 2019
0
0
